Clinical Trial Update: Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer [Phase 2]

View source ↗

Summary

This update reports the completion of a Phase 2 study evaluating the FOLFOX6 regimen as first-line therapy for recurrent or metastatic esophageal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Fudan University | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED